Niraparib Tosylate Monohydrate

Phase 2

Eli Lilly and Company (LLY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

LLYPhase 2$1.1T

Niraparib Tosylate Monohydrate Phase 2 Est. Readout (NICHOL)

Niraparib Tosylate Monohydrate• Ovarian Cancer73

Mar 2027~Estimated

CT.gov

00%

Competitive Landscape

17 competitors in Ovarian Cancer

AZNSaruparib (AZD5305)

Phase 3

View Full Landscape

Drug Information

Target Indication

Ovarian Cancer

Clinical Trial

NCT06594679

Last updated: 10/30/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

BI10773Phase 3

Diabetes Mellitus, Type 2

BI 10773 open labelPhase 3

Diabetes Mellitus, Type 2

Empagliflozin + LinagliptinPhase 3

Diabetes Mellitus, Type 2

Insulin lispro 6 day reservoir in-usePhase 3

Diabetes Mellitus, Type 1

Intracoronary infusion of enriched bone marrow-derived progenitor cellsPhase 3

Myocardial Infarction

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts